APA (7th ed.) Citation

Pozo-Rosich, P., López, J. A. G., Lisewski, P., Aslan, A. N., Seehra, H., Thiry, A., . . . Fullerton, T. (2025). A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications. Cephalalgia, 45(11), 1. https://doi.org/10.1177/03331024251391378

Chicago Style (17th ed.) Citation

Pozo-Rosich, Patricia, et al. "A Phase 4, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Tolerability of Rimegepant for the Prevention of Episodic Migraine in Adults with a History of Inadequate Response to Traditional Oral Preventive Medications." Cephalalgia 45, no. 11 (2025): 1. https://doi.org/10.1177/03331024251391378.

MLA (9th ed.) Citation

Pozo-Rosich, Patricia, et al. "A Phase 4, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Tolerability of Rimegepant for the Prevention of Episodic Migraine in Adults with a History of Inadequate Response to Traditional Oral Preventive Medications." Cephalalgia, vol. 45, no. 11, 2025, p. 1, https://doi.org/10.1177/03331024251391378.